A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

PRNewswire New Delhi [India]1 Translumina was incorporated in 2011 as a sales marketing company specialising in coronary ...

Translumina, established in 2011, focuses on coronary intervention devices and has expanded its manufacturing capabilities and product lines. The company aims to highlight Indian innovation in the ...

Coronary artery disease is the most common type of heart disease and the most common cause of death. Currently, the standard treatment for patients with coronary artery lesions involves the use of ...

1 Department of Cardiovascular Research, Saint Luke’s Mid America Heart Institute, University of Missouri ... disease were randomised to either CABG (n=897) or PCI with drug-eluting stents (DES; n=903 ...

The stent coatings can be broadly classified into three types: biocompatible coatings, drug-delivery coatings and polymer-free coatings/surfaces. Since metallic stent platforms will release ions ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Babies born with a narrowed blood vessel now have a device specifically designed for them, thanks to research conducted at ...

thanks to research conducted at the Smidt Heart Institute and Guerin Children's at Cedars-Sinai. The U.S. Food and Drug Administration recently approved the new stent, a metal mesh tube that keeps ...

For the past century, heart disease has remained the leading ... more than 1 million patients are being treated today with the drug off-label to reduce cardiovascular disease risk.